期刊文献+

Higher radiation dose with a shorter treatment duration improves outcome for locally advanced carcinoma of anal canal

Higher radiation dose with a shorter treatment duration improves outcome for locally advanced carcinoma of anal canal
下载PDF
导出
摘要 AIM: To assess whether radiation dose and duration of treatment influence local control and survival of patients with locally advanced anal cancer treated with definitive chemoradiation. METHODS: Twenty-eight consecutive patients who were treated with definitive radiation therapy for bulky anal cancers (〉 5 cm in size) were reviewed. Nineteen patients had T3 lesions, 8 patients had T4 lesions, and 15 patients had lymph node involvement. The median tumor size was 7.5 cm. All but one patient received concurrent chemoradiation. The median radiation dose was 54 Gy. The median duration of treatment was 58 d. RESULTS: With a median follow-up of 2.5 years in all patients and 7.8 years in living patients, the 2-year local recurrence-free probability was 570 and overall survival rate was 67%. Neither radiation dose nor duration of treatment alone was predictive of either time to local failure or overall survival. However, longer treatment breaks can potentially mask an advantage over higher radiation doses. Therefore, we examined those patients who received ≥ 54 Gy within 60 d, comparing them to the rest of the patients. Of patients who received ≥54 Gy within 60 d, local progression-free probability was 890 versus 420 for the rest of the group (P = 0.01). CONCLUSION: Local failure is a significant problem in locally advanced carcinomas of-the anal canal. Higher radiation doses with limited treatment breaks may offer an increase in local control and survival. AIM: To assess whether radiation dose and duration of treatment influence local control and survival of patients with locally advanced anal cancer treated with definitive chemoradiation. METHODS: Twenty-eight consecutive patients who were treated with definitive radiation therapy for bulky anal cancers (> 5 cm in size) were reviewed. Nineteen patients had T3 lesions, 8 patients had T4 lesions, and 15 patients had lymph node involvement. The median tumor size was 7.5 cm. All but one patient received concurrent chemoradiation. The median radiation dose was 54 Gy. The median duration of treatment was 58 d. RESULTS: With a median follow-up of 2.5 years in all patients and 7.8 years in living patients, the 2-year local recurrence-free probability was 57% and overall survival rate was 67%. Neither radiation dose nor duration of treatment alone was predictive of either time to local failure or overall survival. However, longer treatment breaks can potentially mask an advantage over higher radiation doses. Therefore, we examined those patients who received ≥ 54 Gy within 60 d, comparing them to the rest of the patients. Of patients who received ≥ 54 Gy within 60 d, local progression-free probability was 89% versus 42% for the rest of the group (P = 0.01). CONCLUSION: Local failure is a significant problem in locally advanced carcinomas of the anal canal. Higher radiation doses with limited treatment breaks may offer an increase in local control and survival.
出处 《World Journal of Gastroenterology》 SCIE CAS CSCD 2007年第6期895-900,共6页 世界胃肠病学杂志(英文版)
关键词 Anal carcinoma Locally advanced CHEMORADIATION 肛门癌 辐射剂量 治疗持续时间 局部控制 患者存活
  • 相关文献

参考文献21

  • 1[1]Bartelink H,Roelofsen F,Eschwege F,Rougier P,Bosset IF,Gonzalez DG,Peiffert D,van Glabbeke M,Pierart M.Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer:results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups.J Clin Oncol 1997; 15:2040-2049
  • 2[2]Epidermoid anal cancer:results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy,5-fluorouraciL and mitomycin.UKCCCR Anal Cancer Trial Working Party.UK Co-ordinating Committee on Cancer Research.Lancet 1996; 348:1049-1054
  • 3[3]Flam M,John M,Pajak TF,Petrelli N,Myerson R,Doggett S,Quivey J,Rotman M,Kerman H,Coia L,Murray K.Role of mitomycin in combination with fluorouracil and radiotherapy,and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal:results of a phase III randomized intergroup study.J Clin Oncol 19%; 14:2527-2539
  • 4[4]Gerard JP,Ayzac L,Hun D,Romestaing P,Coquard R,Ardiet JM,Momex F.Treatment of anal canal carcinoma with high dose radiation therapy and concomitant fluorouracil-cisplatinum.Long-term results in 95 patients.Radiother Oncol 1998; 46:249-256
  • 5[5]Peiffert D,Bey P,Pernot M,Guillemin F,Luporsi E,Hoffstetter S,Aletti P,Boissel P,Bigard MA,Dartois D,Baylac F.Conservative treatment by irradiation of epidermoid cancers of the anal canal:prognostic factors of tumoral control and complications.Int J Radiat Oncol Biol Phys 1997; 37:313-324
  • 6[6]Constantinou EC,Daly W,Fung CY,Willett CG,Kaufman DS,DeLaney TF.Time-dose considerations in the treatment of anal cancer.Int J Radiat Oncol Biol Phys 1997; 39:651-657
  • 7[7]Hughes LL,Rich TA,Delclos L,Ajani JA,Martin RG.Radiotherapy for anal cancer experience from 1979-1987.Int J Radiat Oncol Biol Phys 1989; 17:1153-1160
  • 8[8]Nigh SS,Smalley SR,Elman AJ,Paradelo JC,Kooser JA,Reddi R,Evans RG.Conservative Therapy for Anal Carcinoma:an Analysis of Prognostic Factors.Int J Radiat Oncol Biol Phys 1991; 21:224
  • 9[9]Rich TA,Ajani JA,Morrison WH,Ota D,Levin B.Chemoradiation therapy for anal cancer radiation plus continuous infusion of 5-fhiarouradl with or without dsplatdn.Radiother Oncol 1993; 27:209-215
  • 10[10]John M,Pajak T,Flam M,Hoffman J,Markoe A,Wolkov H,Paris K.Dose escalation in chemoradiation for anal cancer:preliminary results of RTOG 92-08.Cancer J Sci Am 1996; 2:205-211

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部